Cooper Companies, Inc. (COO)
Health Care · Health Care Supplies · US stock · S&P 500 component
$57.94
▲ +0.54 (0.94%)
Fair valueFair
$60 +3.7% to fair value
$30fair band $42–$78$90
Day's range
$57.37 – $58.25
52-week range
$51.01 – $89.83
About Cooper Companies, Inc.
Cooper Companies develops and manufactures medical devices through two businesses. CooperVision makes soft contact lenses, which it supplies to eye care professionals and retailers around the world, while CooperSurgical focuses on products for women's health, fertility and newborn care used by hospitals, clinics and fertility specialists.
Revenue comes from the recurring supply of contact lenses and from surgical, diagnostic and fertility products. In the last twelve months it was $4.2 billion, growing at 7.3% a year across the last three years. The operating margin is 12.8%, and the business earns a profit of 4% on the capital invested in it. It has net debt of 3.2 times EBITDA. The company does not pay a dividend. On the site's X-Ray Score it receives 46 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $51.01 – $89.83Volume 3,773,300Daily, split-adjusted
Vitals
Market cap$11.2B
52-week range$51.01 – $89.83
Volume (last day)3,773,300
P/E (TTM)19.9
EBIT / EV yield3.8%
Free-cash-flow yield6.1%
Dividend yieldNo dividend
Revenue (TTM)$4.2B
Net income (TTM)$570M
Operating margin12.8%
Return on capital4.3%
Debt incl. leases$3.2B
Cash & securities$155M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$60model spread $58 – $63
Fair
+3.7% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $58
Undervalued < $42Fair $42 – $78Overvalued > $78
10-year DCF (market-scaled)
$32
Peer multiples
$77
Earnings power floor (not blended)
$22
Fundamentals-adjusted multiple
$71
Growth the price implies
20.2%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
57/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield3.8%
Free-cash-flow yield6.1%
Fair value vs price1.0×
Growth
Weak
46/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)7.3%
EPS growth (3y)-1.2%
Growth consistency100%
Profitability
Weak
37/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital4.3%
Operating margin12.8%
Gross profitability22.0%
Financial health
Weak
42/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA3.2×
Interest cover6.1×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+6.3%
Apr '25
+5.7%
Jul '25
+4.6%
Oct '25
+6.2%
Jan '26
+7.9%
Apr '26
+0.6%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.1B, diluted EPS $2.24.
Compare with peers
ALGN Align Technology Inc61 WST West Pharmaceutical Se...44Other Health Care Supplies companies by X-Ray Score.
Fundamentals checklist
● 3 Good · ● 8 Average · ● 5 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldGood
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalBad
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 42/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.3B | $3.6B | $3.9B | $4.1B |
| Operating income | $506M | $508M | $533M | $706M | $683M |
| Net income | $2.9B | $386M | $294M | $392M | $375M |
| Operating cash flow | $739M | $692M | $608M | $709M | $796M |
| Operating margin | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% |
| Free cash flow | $524M | $450M | $215M | $288M | $434M |
| Diluted EPS | $59.16 | $1.94 | $1.48 | $1.96 | $1.87 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
5 bullish · 1 neutral · 10 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
| SMA 10 | 55.70 | Bullish |
| EMA 10 | 56.12 | Bullish |
| SMA 20 | 55.86 | Bullish |
| EMA 20 | 56.85 | Bullish |
| SMA 50 | 63.55 | Bearish |
| EMA 50 | 60.97 | Bearish |
| SMA 100 | 66.28 | Bearish |
| EMA 100 | 64.55 | Bearish |
| SMA 200 | 70.04 | Bearish |
| EMA 200 | 68.21 | Bearish |
Oscillators (daily)
| RSI (14) | 50.28 | Neutral |
| MACD (12, 26) | -1.58 | Bearish |
| Momentum (12) | 2.49 | Bullish |
| Stochastic %K (14) | 93.17 | Bearish |
| Williams %R (14) | -6.83 | Bearish |
| CCI (20) | 159.3 | Bearish |
Pivot points (classic, last session)
S3 56.58 | S2 56.97 | S1 57.46 | Pivot 57.85 | R1 58.34 | R2 58.73 | R3 59.22 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.00 USD
Yield on today's price
–
Frequency
None in the last year
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 26 Jul 2023 | 0.0300 |
| 20 Jan 2023 | 0.0300 |
| 26 Jul 2022 | 0.0300 |
| 20 Jan 2022 | 0.0300 |
| 26 Jul 2021 | 0.0300 |
| 21 Jan 2021 | 0.0300 |
| 22 Jul 2020 | 0.0300 |
| 22 Jan 2020 | 0.0300 |
| 22 Jul 2019 | 0.0300 |
| 18 Jan 2019 | 0.0300 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
COO SEC filings
9 Sep 2026
10-QSEC EDGAR
Quarterly report
9 Sep 2026
8-KSEC EDGAR
Results of operations; Other events
5 Jun 2026
10-QSEC EDGAR
Quarterly report
4 Jun 2026
8-KSEC EDGAR
Results of operations; Other events
4 May 2026
8-KSEC EDGAR
Director or officer change
8 Apr 2026
8-KSEC EDGAR
Shareholder vote results
6 Mar 2026
10-QSEC EDGAR
Quarterly report
5 Mar 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.